Limitations of presently available glycopeptides in the treatment of Gram-positive infection

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 4, 2001, Pages 53-65

  Ziglam, H M ^a   Finch, R G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antibiotic resistance; Glycopeptide; Gram positive infections; Teicoplanin; Vanocmycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; AVOPARCIN; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; LINEZOLID; METICILLIN; METRONIDAZOLE; NAFCILLIN; PENICILLIN G; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS; ENTEROPATHY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035746948     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00059.x     Document Type: Article

References (150)

1. Vancomycin use - An historical review
2. Mode of action and in vitro activity of vancomycin
3. Vancomycin: An update
4. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations
5. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones
6. Susceptibility of Staphylococcus species and subspecies to teicoplanin
7. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
8. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
9. In-vitro evaluation of cefpirome (HR 810), teicoplanin and four other antimicrobial against enterococci
10. Microbiological properties of teicoplanin
11. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci
12. Evaluation of the teicoplanin broth microdilution and disk diffusion susceptibility tests and recommended interpretive criteria
13. In vitro activity of vancomycin and teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis colonizing catheters
14. Efficacy and safety of teicoplanin in Gram-positive peritonitis in patients on peritoneal dialysis
15. In-vitro susceptibility of Gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin
16. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria
17. A critical review of the in-vitro activity of teicoplanin
18. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains
19. In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus
20. In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis
21. Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus
22. Synergistic effect of ampicillin or vancomycin in combination with decreasing concentrations of streptomycin against enterococci
23. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis
24. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method
25. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci
26. In vitro activity of teichomycin compared with those of other antibiotics
27. Pharmacokinetics of vancomycin in patients with severely impaired renal function
28. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers
29. Prediction of serum vancomycin concentration using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method
30. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit
31. Pharmacokinetics of vancomycin in patients with various degrees of renal function
32. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function
33. Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis
34. Vancomycin and teicoplanin: Something old, something new
35. CDC issues recommendations for preventing spread of vancomycin resistance
36. Recommendations issued for preventing the spread of vancomycin resistance
37. CDC VRE guidelines still relevant
38. Emerging multiresistant strains: Recommended precautions in the emergency room and surgical setting
39. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention
40. Knowledge of Centers for Disease Control and Prevention guidelines for the use of vancomycin at a large tertiary care children's hospital
41. Glycopeptide tolerance in Staphylococcus aureus
42. Vancomycin therapy for methicillin-resistant Staphylococcus aureus
43. Bacteremia due to methicillin-resistant Staphylococcus aureus
44. Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections
45. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: Two-week combination therapy
46. Vancomycin therapy of bacterial endocarditis
47. Vancomycin-aminoglycoside combinations in therapy of endocarditis caused by Enterococcus species and Streptococcus bovis
48. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy
49. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis
50. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
51. Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients
52. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious Gram-positive infections
53. Teichoplanin: A clinical study of treatment of serious infections in hospitalized patients
54. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients
55. 4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin
56. Treatment of antibiotic-associated pseudomembranous colitis
57. Treatment of Clostridium difficile colitis and diarrhea with vancomycin
58. Antibiotic-associated colitis - A review of 66 cases
59. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis
60. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations
61. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study
62. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections
63. Teicoplanin in endocarditis: A multicentre, open European study
64. Teicoplanin in the treatment of Gram-positive-bacterial endocarditis
65. A critical review of the dosage of teicoplanin in Europe and the USA
66. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: Lessons from four EORTC trials
67. The role of Gram-positive therapy in the neutropenic patient
68. Gram-positive infections in granulocytopenic patients: An important issue?
69. Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients
70. Efficacy of the combination of ceftazidime/vancomycin in the first line treatment of infection in neutropenic children
71. A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients
72. Aspects of infections in children with cancer
73. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters
74. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer
75. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients
76. Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated Gram-positive peritonitis?
77. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis - A prospective, randomized comparison of intermittent v continuous therapy
78. Teicoplanin in the treatment of enterococcal endocarditis: Clinical and microbiological study
79. Treatment of antibiotic-associated colitis with vancomycin
80. Relapse of pseudomembranous colitis after vancomycin therapy
81. Relapse of pseudomembranous colitis after vancomycin therapy
82. A review of vancomycin after 15 years use
83. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
84. Mild nephrotoxicity associated with vancomycin use
85. Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats
86. Vancomycin toxicity: A prospective study
87. A prospective study of adverse reactions associated with vancomycin therapy
88. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination
89. Nephrotoxicity of vancomycin, alone and with an aminoglycoside
90. The comparative efficacy and safety of teicoplanin and vancomycin
91. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection
92. Recommendations for preventing the spread of vancomycin resistance
93. Continuous ambulatory peritoneal dialysis (CAPD) peritonitis: The effect of antibiotic on the adherence of coagulase-negative staphylococci to silicone rubber catheter material
94. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis
95. Teicoplanin in the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis
96. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: Effect on cyclosporin A-associated nephrotoxicity
97. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients
98. Teicoplanin: A well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients
99. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies
100. Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes
101. Comparative study of teicoplanin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bactermia
102. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: Preliminary results
103. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection
104. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea
105. Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts
106. Teicoplanin vs. vancomycin for the treatment of serious infections: A randomized trial
107. Recommendations for preventing the spread of vancomycin resistance
108. Recommendations for preventing the spread of vancomycin resistance
109. The epidemiology of intravenous vancomycin usage in a University hospital. A 10-year study
110. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients
111. Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer
112. Retrospective study of teicoplanin as home continuation of hospital-intiated therapy
113. Management of serious staphylococcal infections in the outpatient setting
114. Impact of glycopeptide therapy after hospital discharge on inpatient costs: A comparison of teicoplanin and vancomycin
115. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis
116. Teicoplanin in the treatment of bone and joint infections
117. Glycopeptide resistance in enterococci
118. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405
119. VanD-type glycopeptide-resistant Enterococcus faecium BM4339
120. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a University medical center
121. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
122. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients
123. Nosocomial enterococci resistant to vancomycin - United States, 1989-93
124. Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci
125. Prevalence of vancomycin-resistant enterococci in Europe
126. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
127. Emergence of vancomycin-resistant enterococci in New York City
128. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients
129. Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by glycopeptide-resistant enterococci among hospitalized patients
130. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium
131. Survey of antibiotic resistance among enterococci in North Rhine-Westphalia, Germany
132. Vancomycin-resistant enterococci and use of avoparcin in animal feed: Is there a link?
133. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin
134. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
135. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality?
136. Risk factors for mortality associated with enterococcal bloodstream infections
137. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality
138. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
139. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative
140. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
141. Vancomycin-resistant Staphylococcus aureus
142. Vancomycin-resistant Staphylococcus aureus: An emerging public health threat
143. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
144. Emergence of vancomycin resistance in Staphylococcus aureus
145. Vancomycin resistant staphylococcus reported in Hong Kong
146. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
147. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay
148. Correlation between consumption of antimicrobials in humans and development of resistance in bacteria
149. Emergence of vancomycin resistance in coagulase-negative staphylococci
150. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: A problem of increasing importance